by bstone | Oct 22, 2024 | Uncategorized
Lexington, Mass., October 22, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, today announced the appointment of John Lepore, M.D., to the company’s board of directors. Dr. Lepore brings over 20...
by whicks | Oct 8, 2024 | Uncategorized
Lexington, Mass., October 8, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, today announced the appointment of Anna Truppel-Hartmann, M.D., as Chief Medical Officer. Dr. Truppel-Hartmann brings...
by whicks | Sep 24, 2024 | Uncategorized
Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumors Lexington, Mass., September 24, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors,...
by s2desi5_ksqtherapeutics | Oct 2, 2017 | Uncategorized
– World class executive team led by CEO David Meeker and CSO Frank Stegmeier – – Proprietary CRISPRomics™ Drug Discovery Engine Pinpoints the Best Therapeutic Nodes of Diseases; Product Insights Being Translated into Drug Candidates – Cambridge, Mass., October 2, 2017...
by s2desi5_ksqtherapeutics | Sep 25, 2018 | Uncategorized
– Industry Leader Brings Expertise in Medical, Clinical and Regulatory Affairs in Drug Development – Cambridge, Mass., September 25, 2018 – KSQ Therapeutics today announced the appointment of Richard A. Moscicki, MD, to the company’s Board of Directors. Dr. Moscicki...
